Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma

The benefits and harms of adding long-acting muscarinic antagonists (LAMAs) to inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) for moderate to severe asthma remain unclear.To systematically synthesize the outcomes and adverse events associated with triple therapy (ICS, LABA, and LAMA) vs dual therapy (ICS plus LABA) in children and adults with persistent uncontrolled asthma.MEDLINE, Embase, CENTRAL, ICTRP, FDA, and EMA...